Bioxyne Limited · ASX:BXN
Bioxyne — FY2025 Earnings Presentation
23 slides from Bioxyne's earnings presentation, Aug 29, 2025
Slide 1: FY25 Results Presentation
oe Bisxyne FY25 RESULTS PRESENTATION e | CAMBS, = Ps MOMA a. \ 4 b . oe ; ] . «~ j x a a / i rin’! % (PHARMACEUTICAL GRADE )
Slide 2: Disclaimer
DISCLAIMER This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subjec
Slide 3: FY25 Overview
FY25 OVERVIEW FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 3
Slide 4: FY25 Overview
FY25 OVERVIEW FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Multiple contract wins: +€3.2m Upgraded Guidance to $28.0m Doubled GMP Flower Packing Certificate of GMP compliance (A$5.8m) supply agreement revenue in FY25 and delivered Capacity to 30tn in push with Europe, Canada, Singapore w
Slide 5: Financials
FINANCIALS FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 5
Slide 6: Revenue Growth
REVENUE GROWTH Record quarterly annual revenue of $30.4m delivered, representing an 215% increase on FY24 FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Record annual revenue of $30.4m delivered, REVENUE GROWTH representing a 215% increase on FY24 (PCP). $35.0m Revenue 250% Key Drivers
Slide 7: FY25 Performance
FY25 PERFORMANCE BXN continues to benefit from operational leverage following cost reduction initiatives & material increase in topline revenue FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Profit & Loss ($000's) FY24 FY25 Growth Comment FY25 EBITDA Bridge Revenue $9,659 $30,447 215% Incr
Slide 8: Margin Analysis
MARGIN ANALYSIS Reported Gross Profit impacted by re-allocation of operating employee costs to Other Direct Costs of Sales category FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK MARGIN ANALYSIS FY24 FY25 COMMENT OUTLOOK • New contracts and expansion of existing customer • Primarily Austra
Slide 9: Cash Flow Positive
Cash Flow Positive Strong outlook for remainder of FY25 and beyond, following execution of significant contracts, with customer base continuing to build and cross selling initiatives driving customer revenue growth FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK BXN has delivered positive
Slide 10: Australian Market Growth
AUSTRALIAN MARKET GROWTH FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 10
Slide 11: Production Capacity
PRODUCTION CAPACITY Recent investment into additional equipment & facilities has underpinned a substantial increased production capability & will continue to simultaneously underpin the initial rollout of EU & UK strategy FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK CURRENT AUSTRALIAN MA
Slide 12: Australian Growth Strategy
AUSTRALIAN GROWTH STRATEGY Australian medicinal cannabis prescriptions continue to grow. BXN will continue to aggressively invest in growing domestic market share FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK AUSTRALIAN MEDICINAL CANNABIS APPROVALS1 AUSTRALIAN MARKET GROWTH STRATEGY 1304k
Slide 13: International Market Growth
AUSTRALIAN MARKET GROWTH FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 13
Slide 14: EU Market Entry
EU MARKET ENTRY Czechia facility to supply rapidly growing European markets with construction beginning imminently FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK BUILD MANUFACTURING & CONTROLLED TARGETING 5-10% OF GERMAN MEDICAL CANNABIS FLOWER IN FY26 PURSUE STRATEGIC ENTRIES SUSTANCE SUP
Slide 15: UK Market Entry
UK MARKET ENTRY The UK represents a material opportunity for the Company with the replication of the existing QLD facility set to supply a rapidly growing market with similar customer dynamics FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Q1 FY26 - ESTABLISH DISTRIBUTION CURRENT ADDRESSAB
Slide 16: Outlook
OUTLOOK FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK 16
Slide 17: Outlook
OUTLOOK Substantial growth anticipated in FY26 with multiple growth drivers underpinning revenue & margin expansion FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK EUROPE UK AUS Continue to accelerate Continue to progress controlled Invest in inventory to meet controlled drugs and GMP drugs
Slide 18: FY26 Guidance
FY26 GUIDANCE The Board provides guidance of $65m to $75m Revenue for FY26 and $11.5m to $13.5m Underlying EBITDA FY25 OVERVIEW FINANCIALS AUS GROWTH INTL. GROWTH OUTLOOK Revenue Drivers FY26 REVENUE GUIDANCE RANGE Growing demand from existing Australian clients launching new product lines and pla
Slide 19: Appendix
APPENDIX 19
Slide 20: Balance Sheet
BALANCE SHEET The Company remains well positioned to continue to fund it’s domestic & international growth strategies Balance Sheet ($000's) FY25 FY24 Comment Assets Current Assets Cash and cash equivalents 7,668 1,028 Trade receivables 2,355 978 Current tax receivables 1,172 545 Other current asset
Slide 21: Board & Management
BOARD & MANAGEMENT Mr. Anthony Ho Samuel Watson Jason Hine Guy Robertson B. Com (UNSW), CA, FAICD, FCIS, FGIA BSc Finance and Economics BA Economics and Commerce B. Com (Hons.) CA Non-executive Chairman Managing Director Executive Director CFO & Company Secretary • Tony is an experienced company • S
Slide 22: Corporate Snapshot
CORPORATE SNAPSHOT $0.06 60m $0.04 40m $0.02 20m - - Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Volume Share Price CORPORATE SNAPSHOT (JULY-2025) MAJOR SHAREHOLDERS Shareholder Shares (m) % Shares on Issue 2,171m Breathe International Ltd 576,268,527 26.53 Ki
Slide 23: Contact
CONTACT JAMES EMONSON ALPINE CAPITAL Corporate Advisor jemonson@alpinecapital.au